logo
Plus   Neg
Share
Email

IPO Lockup Expiration: Aligos Therapeutics

aligostherapeutics april12 lt

The lockup period of South San Francisco, California-based Aligos Therapeutics (ALGS) ends today, i.e., April 14, 2021.

Founded in 2018, Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases.

The most advanced drug candidate is ALG-010133, currently in phase 1 trial in patients with chronic hepatitis B, or CHB, for which safety and antiviral data from the initial cohort(s) is expected in the second half of 2021.

Also in the pipeline are:

ALG-000184, which is in phase I clinical trial for the treatment of chronic hepatitis B, with safety and antiviral data from the initial cohort(s) expected in the second half of 2021.

ALG-020572, for the treatment of chronic hepatitis B, for which phase I study is expected to be initiated in the second half of 2021.

ALG-125097, for the treatment of chronic hepatitis B, and the phase I study is expected to be initiated in the second half of 2021.

ALG-055009 for the treatment of NASH, and the CTA-enabling toxicology studies are planned for the second half of 2021.

Aligos Therapeutics made its debut on the Nasdaq Global Select Market on October 16, 2020, offering its shares at a price of $15 each and as mentioned above, the 180 day lockup period expires on April 14.

ALGS opened the first day of trading on October 16 at $17.40 and closed at $14.85 that day. The stock has thus far hit a low of $12.82 and a high of $37.51.

ALGS closed Tuesday's trading at $20.60, down 3.47%.

For comments and feedback contact: editorial@rttnews.com

Follow RTT